首页> 外文期刊>Clinical drug investigation >Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995
【24h】

Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995

机译:加拿大人口中苯二氮卓类药物的使用,滥用和危害:1995年以来数据与发展的综合叙事回顾

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Benzodiazepines are commonly prescribed psycho-pharmaceuticals (e.g., for anxiety, tension, and insomnia); they are generally considered safe but have potential adverse effects. Benzodiazepine use in Canada versus internationally is comparably high, yet no recent comprehensive review of use, misuse, or related (e.g., morbidity, mortality) harm at the population level exists; the present review aimed to fill this gap. We searched four key scientific literature databases (Medline, CINAHL, EBM Reviews, and Web of Science) with relevant search terms, and collected relevant "gray literature" (e.g., survey, monitoring, government reports) data published in 1995-2015. Two reviewers conducted data screening and extraction; results were categorized and narratively summarized by key sub-topics. Levels of benzodiazepine use in the general population have been relatively stable in recent years; medical use is generally highest among older adults. Rates of non-medical use are fairly low in general but higher in marginalized (e.g., street drug use) populations; high and/or inappropriate prescribing appears common in older adults. Benzodiazepines are associated with various morbidity outcomes (e.g., accidents/injuries, cognitive decline, sleep disturbances, or psychiatric issues), again commonly observed in older adults; moreover, benzodiazepines are identified as a contributing factor in suicides and poisoning deaths. Overall there is a substantial benzodiazepine-related health problem burden-although lower than that for other psycho-medications (e.g., opioids)-in Canada, mainly as a result of overuse and/or morbidity. National benzodiazepine prescription guidelines are lacking, and few evaluated interventions to reduce benzodiazepine-related problems exist. There is a clear need for reducing inappropriate benzodiazepine use and related harm in Canada through improved evidence-based practice as well as monitoring and control.
机译:苯二氮卓类药物通常被指定为心理药物(例如,用于焦虑,紧张和失眠);它们通常被认为是安全的,但具有潜在的不利影响。加拿大与国际上的苯二氮卓类药物使用量相当,但最近尚无关于在人群一级使用,滥用或相关(例如发病率,死亡率)危害的全面综述;本审查旨在填补这一空白。我们使用相关搜索词搜索了四个关键的科学文献数据库(Medline,CINAHL,EBM评论和Web of Science),并收集了1995-2015年发布的相关“灰色文献”(例如调查,监测,政府报告)数据。两名审查员进行了数据筛选和提取;通过主要子主题对结果进行分类和叙述性总结。近年来,一般人群中苯二氮卓的使用水平一直相对稳定。在老年人中,医疗使用通常最高。一般而言,非医疗用途的使用率较低,而边缘化(例如街头毒品使用)人群的使用率较高;高和/或不合适的处方在老年人中很常见。苯二氮卓类药物与各种发病结果有关(例如事故/伤害,认知能力下降,睡眠障碍或精神病),这在老年人中也很常见;此外,苯并二氮杂被认为是自杀和中毒死亡的一个促成因素。总体而言,加拿大的苯并二氮杂health相关的健康问题负担重重,尽管比其他精神药物(例如阿片类药物)要低,这主要是由于过度使用和/或发病所致。缺乏国家苯并二氮杂类处方指南,几乎没有评估减少苯并二氮杂类相关问题的干预措施。在加拿大,显然有必要通过改进循证实践以及监测和控制来减少不适当的苯二氮卓类药物使用及相关危害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号